Chemotherapy patients
Conditions
Interventions
Control group:Conventional antiemetic regimen: Ondansetron injection (Aobei), 8 mg, was administered by intravenous bolus 30 minutes before each chemotherapy infusion and again at 16:00 on the same da
Experimental group:On the basis of the control group regimen, participants wore a low-frequency Electronic Antiemetic Device (EAD
Faluoshi) prior to the initiation of chemotherapy and continued its use until the day chemotherapy was completed. The Neiguan acupoint (PC6) is located on the palmar aspect of the forearm, 2 cun proxi
Sponsors
Shandong Provincial Hospital Affiliated to Shandong First Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age > 18 years old; 2. Patients with a definite pathological diagnosis of malignant tumors; 3. With a moderate to high level of nausea caused by chemotherapy drugs, and the chemotherapy regimen lasting for at least 1 cycle; 4. KPS assessment >= 60 points; 5. No nausea or vomiting within 24 hours before chemotherapy, and no other anti-nausea drugs used; 6. Voluntarily use the low-frequency anti-nausea device and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Those with severe diseases of the heart, liver, kidney, immune system and hematopoietic system; 2. Pregnant women and lactating women; 3. Patients with brain metastasis from malignant tumors, increased intracranial pressure, digestive tract obstruction, severe liver and kidney dysfunction, and persistent vomiting caused by brain tumors, cerebrovascular diseases or other reasons; 4. Those with implanted metal devices such as cardiac pacemakers, blood glucose meters, and cochlear implants; 5. Those allergic to metals or with damaged skin at the wearing site; 6. Those with cognitive impairment or mental disorders.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete remission rate of delayed chemotherapy-induced nausea and vomiting; | — |
Secondary
| Measure | Time frame |
|---|---|
| Complete remission rate of acute chemotherapy-induced nausea and vomiting;Overall response rates of acute and delayed CINV;Severity of nausea and vomiting;Quality of life;Safety outcomes; | — |
Countries
China
Contacts
Public ContactWeifeng Li
Shandong First Medical University Affiliated Provincial Hospital
Outcome results
None listed